C79.51
C79.51 — Secondary malignant neoplasm of bone
Billable / specific codeICD-10-CM
C79.51 is a billable, specific ICD-10-CM code for secondary malignant neoplasm of bone. It is valid for submission on a claim.
Risk adjustment
C79.51 risk-adjusts. Under the CMS-HCC V28 model it maps to this category:
- HCC 18 Cancer Metastatic to Bone, Other and Unspecified Metastatic Cancer; Acute Leukemia Except Myeloid2.341 RAF
Coefficient shown for the Community Non-dual Aged segment. A higher HCC in the same hierarchy will suppress this one, so capturing it does not always add score.
Medicare coverage
C79.51 is named in 76 Medicare coverage policies — 76 listing it as supporting medical necessity. Which of them applies to you depends on your Medicare contractor, and coverage genuinely differs by state.
- A52399Billing and Coding: Denosumab (Prolia®, Xgeva®, Jubbonti®, Wyost®, Ospomyv™,Xbryk™,Bomyntra®, Conexxence®, Stoboclo®, Osenvelt®,Bildyos®, Bilprevda®)
- A52421Billing and Coding: Ibandronate Sodium
- A52453Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs
- A52453Billing and Coding: Luteinizing Hormone-Releasing Hormone (LHRH) Analogs
Related codes at this level
Codes that share C79.5. If C79.51 is not quite right, the correct code is usually one of these.
Questions about C79.51
- Is C79.51 a billable ICD-10-CM code?
- Yes. C79.51 is a billable, specific ICD-10-CM code and is valid for submission on a claim.
- Where does C79.51 sit in the tabular list?
- Neoplasms (C00-D49), in the block Malignant neoplasms of ill-defined, other secondary and unspecified sites (C76-C80).